Alzheimer’s disease: a new therapeutic strategy
Probiodrug’s novel approach to Alzheimer’s targets a modified form of ß-amyloid, which has a key role in the formation of toxic Aß oligomers. The company’s lead product is a first-in-class oral small molecule glutaminyl cyclase inhibitor